Proliferating cell nuclear antigen in epithelial ovarian cancer: relation to results at second-look laparotomy and survival

Gynecol Oncol. 1992 Nov;47(2):191-5. doi: 10.1016/0090-8258(92)90105-r.

Abstract

We determined the proliferative index (PI) of 92 previously untreated advanced epithelial ovarian cancers using PCNA/cyclin immunostaining and image analysis quantitation. In this retrospective study, there was a relationship between tumor PI and 5-year survival. For patients with a tumor PI greater than the median, the estimated 5-year survival was 44%; for patients with a tumor PI below the median, the estimated 5-year survival was 15% (P = 0.003). This may partly reflect sensitivity to chemotherapy, as those patients with more rapidly proliferating tumors were more likely to achieve a pathologic complete response to platinum-based therapy.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Analysis of Variance
  • Carcinoma / chemistry*
  • Carcinoma / pathology
  • Carcinoma / surgery
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Middle Aged
  • Neoplasm Proteins / analysis*
  • Nuclear Proteins / analysis*
  • Ovarian Neoplasms / chemistry*
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / surgery
  • Proliferating Cell Nuclear Antigen
  • Proportional Hazards Models
  • Reoperation
  • Retrospective Studies
  • Survival Analysis

Substances

  • Neoplasm Proteins
  • Nuclear Proteins
  • Proliferating Cell Nuclear Antigen